PTC Therapeutics Board Approves Up to $500 Million Stock Buyback
The company's board approved plans to repurchase up to $500 million of its common stock.
Related stories
Iveco Group Reports Q3 Revenue of €3.16 Billion
M impact | EQUITY | Nov 03, 2026, 08:03 PM UTC
Gartner Reports Lower Q3 Revenue
Gartner reported lower Q3 revenue on Tuesday.
M impact | EQUITY | Nov 03, 2026, 08:03 PM UTC
Meridian Shares Fall 6.7% After DA Davidson Downgrade
Meridian shares fell 6.7% after DA Davidson downgraded the stock.
M impact | EQUITY | Nov 03, 2026, 08:02 PM UTC
Business First Bancshares Reports Third-Quarter 2026 Results
Interest income rose 7.4% year over year to $127.5 million and net income available to common shareholders increased 7.9% to $23.2 million. Diluted EPS was $0.71, down from $0.73.
M impact | EQUITY | Nov 03, 2026, 08:01 PM UTC
Iveco Q3 EBIT Falls; Net Revenue Rises
Iveco reported lower third-quarter 2026 EBIT and higher net revenue year over year.
M impact | EQUITY | Nov 03, 2026, 08:01 PM UTC
US session market picture: S&P 500 +0.2%, Nasdaq 100 +0.44%; EUR/USD +0.03%, WTI +0.12%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.2 percent, Nasdaq futures is up 0.44 percent, Dow futures is down 0.48 percent and Russell futures is up 0.33 p
M impact | EQUITY | Nov 03, 2026, 08:00 PM UTC